Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs

Rhea-AI Summary

Innocan Pharma (OTCQB: INNPD) announced peer-reviewed publication of a randomized, blinded, placebo-controlled crossover trial showing a single 7 mg/kg subcutaneous injection of LPT-CBD produced statistically significant pain and function improvements in dogs with osteoarthritis versus placebo.

Key results: n=8 dogs, owner-reported function improved in 100% vs 25% (p=0.0217); reductions in lameness (p=0.033) and pain (p=0.005); measurable plasma CBD up to 4 weeks; only minor, transient adverse events. Ongoing FDA discussions noted.

Positive

• Owner-reported function improvement: 100% after LPT-CBD versus 25% placebo (p=0.0217)
• Statistically significant reductions in lameness (p=0.033) and pain (p=0.005)
• Sustained plasma CBD concentrations measurable for up to 4 weeks after single 7 mg/kg dose
• Well tolerated: only minor, self-resolving fever and transient injection-site swelling reported

Negative

• Small sample size: only eight client-owned dogs enrolled, limiting statistical power and generalizability
• Efficacy demonstrated only in veterinary subjects with up to four weeks follow-up; no human efficacy data reported

Key Figures

Registered units: 2,350,000 units IPO price range: $5.00–$6.00 per unit Warrant exercise price: $6.875 +5 more

8 metrics

Registered units 2,350,000 units Form F-1/A NYSE American IPO registration

IPO price range $5.00–$6.00 per unit Expected NYSE American offering range

Warrant exercise price $6.875 Each warrant exercisable for five years

Expected net proceeds $10.89 million Assumed $5.50 per unit, before over-allotment

Human LPT-CBD R&D allocation $6.5 million Planned use of IPO proceeds

Veterinary LPT-CBD R&D allocation $2.5 million Planned use of IPO proceeds

Sample size 8 dogs Naturally occurring osteoarthritis clinical trial

LPT-CBD dose 7 mg/kg Single subcutaneous injection vs placebo

Market Reality Check

Vol: Reported volume is 0 vs 2...

normal vol

Volume Reported volume is 0 vs 20-day average of 336 shares, indicating limited pre-news activity. normal

Technical Price is trading below the 200-day MA at 11.04, pointing to a pre-existing downtrend or weak stance.

Market Pulse Summary

This announcement highlights statistically significant, placebo-controlled evidence that a single 7 ...

Analysis

This announcement highlights statistically significant, placebo-controlled evidence that a single 7 mg/kg LPT-CBD injection improved pain and function in dogs with osteoarthritis for up to 4 weeks, with only transient adverse events reported. In parallel, F-1/A filings outline a planned NYSE American listing of 2,350,000 units and targeted funding for both human and veterinary LPT-CBD R&D. Investors may watch for larger trials, regulatory feedback and progress on the U.S. offering process.

Key Terms

pharmacokinetics, placebo-controlled, crossover clinical trial, subcutaneously, +3 more

7 terms

pharmacokinetics medical

"Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

placebo-controlled medical

"a randomized, blinded, placebo-controlled, crossover clinical trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

crossover clinical trial medical

"placebo-controlled, crossover clinical trial" in the journal"

A crossover clinical trial tests two or more treatments by having the same participants receive each treatment in sequence, with a break between them so each person serves as their own comparison. For investors, this design can make early studies smaller, faster and more efficient—reducing cost and variability—yet it can also introduce risks if effects of one treatment carry over into the next or if timing complicates results, which can affect regulatory evaluation and the perceived value of a drug or device.

subcutaneously medical

"liposomal synthetic cannabidiol injected subcutaneously in dogs"

Given or delivered beneath the skin into the fatty layer just under the surface, usually by injection or a small device. For investors, whether a medicine is given subcutaneously affects how easy it is for patients to use, how often doses are needed, and the cost and complexity of manufacturing and regulation—think of it like placing a slow-release patch under a carpet instead of pouring medicine on top of it, which changes convenience and ongoing demand.

warrant financial

"each with one common share and one warrant, plus 2,350,000 common"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

initial public offering financial

"for an initial public offering on the NYSE American."

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

foreign private issuer regulatory

"The company, an emerging growth company and foreign private issuer, focuses on"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

AI-generated analysis. Not financial advice.

HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial" in the esteemed peer reviewed journal Frontiers in veterinary science (https://doi.org/10.3389/fvets.2025.1746266) ⁽¹⁾.

Key findings include:

• Significant improvement in behavior/function reported by owners (p = 0.0217), with 100% of dogs showing improved function after LPT-CBD vs 25% after placebo.
• Significant reduction in lameness (Visual Lameness Scale; p = 0.033) and pain (interactive VAS; p = 0.005) following LPT-CBD administration in comparison to placebo.
• LPT-CBD injection provided a sustained-release profile, with measurable plasma CBD concentrations lasting up to 4 weeks.
• All dogs tolerated LPT-CBD, with only minor, self-resolving adverse events: a short-lived (~2-day) fever and a transient injection-site swelling that was resolved within a few days without treatment.

In follow-up to our recent publication demonstrating the long-acting effects of LPT-CBD in dogs with osteoarthritis ⁽²⁾, the present study evaluated LPT-CBD effect compared with placebo. Eight clients-owned dogs suffering from naturally occurring osteoarthritis received two subcutaneous injections in a randomized, blinded, crossover design: synthetic CBD in liposomes (LPT-CBD) 7 mg/kg and placebo (empty liposomes of identical amount and lipid composition) administered four weeks apart. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations and to evaluate hematological and biochemical profiles before and up to 4-weeks post-injections. Efficacy was assessed via activity monitoring collar and scorings by owners and two veterinary specialists.

This study demonstrates that a single subcutaneous injection of LPT-CBD produced sustained improvements in long-term pain-related outcomes and overall, wellbeing in client-owned dogs with naturally occurring osteoarthritis for up to four weeks, with a statistically significant superiority over placebo. The observed clinical benefit is concordant with sustained plasma CBD concentrations persisting for up to four weeks following administration.

"LPT-CBD has been repeatedly demonstrated to have a pain relief effect across multiple efficacy studies in dogs, goats, and other animals," said Professor Chezy Barenholz, Head of the Advisory Board. "However, this study is particularly important because it shows the clear advantages of LPT-CBD over the liposomal placebo."

Dr. Eyal Kalo, Vice President of Research and Development, added: "We are encouraged by these results, particularly given LPT-CBD's potential as a long-acting approach to pain management in both veterinary and human settings. We have initiated ongoing discussions with FDA, including the Center for Veterinary Medicine (CVM) and the human analgesic and anesthetic department of the FDA, to support the advancement of LPT-CBD across both markets."

Reference:
⁽¹⁾ Yael Shilo-Benjamini et al, Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial, Front. Vet. Sci., 19 January 2026.
⁽²⁾ Yael Shilo-Benjamini et al, Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis, Front. Vet. Sci., 23 August 2023.

About Innocan:

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.

www.innocanpharma.com

Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/innocan-pharma-announces-lpt-cbd-demonstrates-pain-relief-over-placebo-results-from-a-randomized-blinded-clinical-study-in-dogs-302682620.html

SOURCE Innocan Pharma Corporation

FAQ

What did Innocan Pharma (INNPD) announce on February 9, 2026 about LPT-CBD in dogs?

According to the company, a peer-reviewed randomized, blinded crossover trial showed single 7 mg/kg LPT-CBD injections improved pain and function versus placebo. The n=8 study reported significant owner and clinical scores and measurable plasma CBD for up to four weeks.

How effective was LPT-CBD versus placebo in the INNPD dog trial reported February 2026?

According to the company, LPT-CBD produced statistically significant benefit: 100% of dogs improved vs 25% on placebo (p=0.0217). Clinical measures also showed reduced lameness (p=0.033) and pain (p=0.005).

What dose and duration of effect did INNPD report for LPT-CBD in the February 9, 2026 release?

According to the company, the trial used a single subcutaneous 7 mg/kg LPT-CBD injection and observed measurable plasma CBD concentrations and clinical improvements lasting up to four weeks post-dose.

Were there safety concerns reported for LPT-CBD in the INNPD veterinary trial?

According to the company, all dogs tolerated LPT-CBD with only minor, self-resolving events: a short-lived ~2-day fever and transient injection-site swelling that resolved without treatment within days.

What are the limitations of the INNPD LPT-CBD dog study announced February 2026?

According to the company, the trial enrolled eight client-owned dogs in a crossover design and followed outcomes up to four weeks, which limits broader generalizability and longer-term safety or efficacy conclusions.